Skip to main content

Table 1 Baseline patient demographics and clinical data

From: The effectiveness of topical colloidal silver in recalcitrant chronic rhinosinusitis: a randomized crossover control trial

  Group 1 (n = 8) Group 2 (n = 12)
Mean age (range in years) 65.8 (44–86) 62.3 (45–84)
Female, n (%) 6 (75.0) 2 (16.7)
CRS symptoms ≤5 years, n (%) 1 (12.5) 2 (16.7)
CRS symptoms 6 or more years, n (%) 7 (87.5) 10 (83.3)
Current smoker, n (%) 0 (0) 0 (0)
Past smoker, n (%) 3 (37.5) 4 (33.3)
Asthma, n (%) 3 (37.5) 4 (33.3)
Environmental allergies, n (%) 6 (75.0) 6 (50.0)
Number of surgeries, mean (SD) 2.5 (1.9) 3.1 (2.5)
Current topical saline irrigation, n (%) 7 (87.5) 12 (100.0)
Oral steroid use last 12 months, n (%) 7 (87.5) 10 (83.3)
Oral steroid use during study, n (%) 1 (12.5) 1 (8.3)
Oral antibiotic use last 12 months, n (%) 8 (100.0) 11 (91.7)
Oral antibiotic use during study, n (%) 1 (12.5) 0 (0.0)
Baseline SNOT-22 score, mean (SD) 59.3 (19.4) 52.8 (19.2)
Baseline LK score, mean (SD) 7.8 (2.2) 6.8 (2.3)
  1. CRS chronic rhinosinusitis, SD standard deviation, SNOT-22 Sino Nasal Outcome Test, LK- Lund-Kennedy